. High anti-pegloticase antibody titer was associated with a failure to maintain pegloticase-induced normalization of uric acid. The impact of anti-PEG antibodies on patients' responses to other PEG-containing therapeutics is unknown.
There was a higher incidence of infusion reactions in patients with high anti-pegloticase antibody titer: 53% (16 of 30) in the Krystexxa every 2 weeks group compared to 6% in patients who had undetectable or low antibody titers.
As with all therapeutic proteins, there is a potential for immunogenicity. The observed incidence of antibody positivity in an assay is highly dependent on several factors including assay sensitivity and specificity and assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the comparison of the incidence of antibodies to pegloticase with the incidence of antibodies to other products may be misleading.
Ads by Google
Recovery Works, Hong Kong
Confidential addiction assessment, treatment and intervention services
www.1212.hk
Considering chemotherapy?
Can you take it with paw paw? This question answered and more.
www.pawpawresearch.com
Aspergers: Causes & Cures
Learn Treatments To Help Your Child Be Happy And Content In Who He Is!
www.AspergersSociety.org
Drug Interactions
No studies of interactions of Krystexxa with other drugs have been conducted.
Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients' responses to other PEG-containing therapeutics is unknown.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C
A complete eva luation of the reproductive and developmental toxicity of pegloticase has not been completed. Adequate animal reproduction studies have not been conducted with Krystexxa. It is not known whether Krystexxa can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There are no adequate and well-controlled studies in pregnant women. Krystexxa should be used during pregnancy only if clearly needed.
Pegloticase was not teratogenic in rats administered 0, 5, 10, or 40 mg/kg twice weekly by the intravenous route on gestation days 6 through 16 (the doses are approximately 6-fold to 50-fold higher than the maximum recommended human dose (MRHD) of 8 mg (0.133 mg/kg based on a 60 kg person) every 2 weeks based on a mg/m2 comparison).
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is not recommended to administer Krystexxa to a nursing mother.
Pediatric Use
The safety and effectiveness of Krystexxa in pediatric patients less than 18 years of age have not been established.
Geriatric Use
Of the total number of patients treated with Krystexxa 8 mg every 2 weeks in the controlled studies, 34% (29 of 85) were 65 years of age and older and 12% (10 of 85) were 75 years of age and older. No overall differences in safety or effectiveness were observed between older and younger patients, but greater sensitivity of some older individuals cannot be ruled out. No dose adjustment is needed for patients 65 years of age and older.
Renal Impairment
No dose adjustment is required for patients with renal impairment. A total of 32% (27 of 85) of pat |
